Medincell gained almost 4% on the Paris Bourse on Tuesday, after announcing its intention to present its R&D advances in injectable technologies at an upcoming congress.

The biopharmaceutical company plans to unveil its innovations at the CRS 2024 conference, to be held from July 8 to 12 in Bologna (Italy).

In particular, the company intends to unveil 'BEPO Star', its new process designed to improve the controlled administration of a greater number of drugs and extend its application to new therapeutic areas.

More generally, the company explains that it wants to offer cutting-edge therapeutic options in areas where it is in a position to make a difference, such as psychiatry, oncology, obesity and pain management.

"Taking part in the CRS conference is an opportunity for us to present some of our recent achievements, and demonstrates our commitment to establishing solid partnerships with the academic world and pharmaceutical companies", explained its R&D Director, Adolfo Lopez-Noriega.

Organized by the Controlled Release Society, the CRS annual conference is dedicated to the science and technology of controlled release.

Medincell shares are up over 100% year-to-date.

Copyright (c) 2024 CercleFinance.com. All rights reserved.